Bristol Myers Squibb Co. (BMY)
67.66
+0.74
(+1.11%)
USD |
NYSE |
Sep 02, 16:00
67.66
0.00 (0.00%)
After-Hours: 17:53
Bristol Myers Squibb Research and Development Expense (TTM) : 9.548B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.548B |
| March 31, 2026 | 9.494B |
| December 31, 2025 | 9.492B |
| September 30, 2025 | 9.719B |
| June 30, 2025 | 9.639B |
| March 31, 2025 | 9.672B |
| December 31, 2024 | 10.13B |
| September 30, 2024 | 9.818B |
| June 30, 2024 | 9.643B |
| March 31, 2024 | 9.606B |
| December 31, 2023 | 9.213B |
| September 30, 2023 | 9.247B |
| June 30, 2023 | 9.429B |
| March 31, 2023 | 9.492B |
| December 31, 2022 | 9.411B |
| September 30, 2022 | 9.508B |
| June 30, 2022 | 10.40B |
| March 31, 2022 | 11.35B |
| December 31, 2021 | 11.35B |
| September 30, 2021 | 11.54B |
| June 30, 2021 | 10.78B |
| March 31, 2021 | 9.993B |
| December 31, 2020 | 10.08B |
| September 30, 2020 | 9.283B |
| June 30, 2020 | 8.149B |
| Date | Value |
|---|---|
| March 31, 2020 | 6.975B |
| December 31, 2019 | 5.959B |
| September 30, 2019 | 5.329B |
| June 30, 2019 | 5.229B |
| March 31, 2019 | 6.336B |
| December 31, 2018 | 6.266B |
| September 30, 2018 | 6.319B |
| June 30, 2018 | 6.536B |
| March 31, 2018 | 5.208B |
| December 31, 2017 | 5.209B |
| September 30, 2017 | 5.012B |
| June 30, 2017 | 4.671B |
| March 31, 2017 | 4.71B |
| December 31, 2016 | 4.615B |
| September 30, 2016 | 4.576B |
| June 30, 2016 | 4.57B |
| March 31, 2016 | 5.299B |
| December 31, 2015 | 5.179B |
| September 30, 2015 | 5.045B |
| June 30, 2015 | 4.896B |
| March 31, 2015 | 3.998B |
| December 31, 2014 | 3.928B |
| September 30, 2014 | 3.844B |
| June 30, 2014 | 3.754B |
| March 31, 2014 | 3.747B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Pfizer Inc. | 10.82B |
| AstraZeneca PLC | 14.21B |